arrow
G

Gregg J. Silverman

Department of Medicine
H指数:59
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responses

Natalizumab和fumarate治疗以不同的方式调节多发性硬化患者中的CD4+ T细胞和B细胞亚型,而不会影响持久的COVID-19疫苗应答。

2025-11-190
OAAI
Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination
2024-05-071
OA
Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies
2022-09-2711
OA
Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study
2022-04-0122
OAAI
Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus
2021-03-3077
OAAI